SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
UCB S.A. (UCBJF) trades at a trailing P/E of 40.0, forward P/E of 30.8. Trailing earnings yield is 2.50%, forward earnings yield 3.25%. PEG 0.81 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 40.0).
- Forward P/E 30.8 (down from trailing 40.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.81 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 2.50% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 3.25% as earnings recover.
Overall SharesGrow Score: 79/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — UCBJF
Valuation Multiples
P/E (TTM)40.0
Forward P/E30.8
PEG Ratio0.81
Forward PEG1.03
P/B Ratio0.00
P/S Ratio8.06
EV/EBITDA0.0
Per Share Data
EPS (TTM)$8.20
Forward EPS (Est.)$10.66
Book Value / Share$0.00
Revenue / Share$40.73
FCF / Share$0.00
Yields & Fair Value
Earnings Yield2.50%
Forward Earnings Yield3.25%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$5.52 |
$4.18B |
$520M |
12.4% |
| 2017 |
$8.00 |
$4.53B |
$753M |
16.6% |
| 2018 |
$8.49 |
$4.63B |
$800M |
17.3% |
| 2019 |
$4.23 |
$4.91B |
$792M |
16.1% |
| 2020 |
$3.77 |
$5.35B |
$732M |
13.7% |
| 2021 |
$5.45 |
$5.78B |
$1.06B |
18.3% |
| 2022 |
$2.15 |
$5.52B |
$418M |
7.6% |
| 2023 |
$1.76 |
$5.25B |
$343M |
6.5% |
| 2024 |
$5.48 |
$6.15B |
$1.07B |
17.3% |
| 2025 |
$8.20 |
$7.74B |
$1.56B |
20.1% |
